Goal 2: Reduce Human Disease

The Use of Therapeutic Apheresis to Reduce Circulating Levels of Galectin-3 and other Cancer and Inflammation Promoting Factors

Inflammation plays roles in cancer initiation, promotion, and progression. Elevated circulating galectin-3 (Gal-3) protein and other cancer and inflammation promoting factors (CIPFs) such as C-reactive protein and VEGF are associated with tumorigenesis and may play causative roles. Plasma Gal-3 is a biomarker, prognosticator, and pathogenic mediator of diverse cancers and is emerging as a therapeutic target. Preliminary research demonstrated reduction in galectin-3 and CIPF's with highly promising clinical benefits in patients with advanced cancer with the use of apheresis in conjunction with chemotherapy.

Tags (Keywords associated with the idea)


33 net votes
40 up votes
7 down votes
Idea No. 848